4.25
+0.12(+2.91%)
Currency In USD
| Previous Close | 4.13 |
| Open | 4.09 |
| Day High | 4.25 |
| Day Low | 4.01 |
| 52-Week High | 4.62 |
| 52-Week Low | 0.4 |
| Volume | 2.61M |
| Average Volume | 3.49M |
| Market Cap | 719.82M |
| PE | 14.17 |
| EPS | 0.3 |
| Moving Average 50 Days | 3.74 |
| Moving Average 200 Days | 2.27 |
| Change | 0.12 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) 10 years ago, it would be worth $205.41 as of December 17, 2025 at a share price of $4.25. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $562.91 as of December 17, 2025 at a share price of $4.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and ch
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Nov 04, 2025 2:15 PM GMT
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with